提醒成功

搜索
产品规范 | |
---|---|
Type | In Vivo - Reseach Grade Antibody |
Host | CHO cells |
catalog# | B00043 |
Application | Flow cytometry, animal model study |
Aliases | cytotoxic T-lymphocyte?associated antigen 4, cytotoxic T-lymphocyte antigen 4, CD152, CTLA4 |
Size/Concentration | 1mg/5mg/20mg |
Isotype | Human IgG4 |
Storage | Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | Human CTLA-4 |
Formulation | PBS, pH 7.4 |
Description |
---|
What is Ipilimumab biosimilar research grade? Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors. |
Ipilimumab Biosimilar, Human CTLA-4 Monoclonal Antibody B00043
规格:
- 1mg
- 5mg
- 20mg
数量:
-
+
说明书:


¥1300
-
咨询
-
收藏

